major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
rais pt strong busi
momentum surprisingli low
rais estim pt
manag continu deliv strong busi momentum
tax reform lower tax rate half
maintain ew anticip stock appreci current
level note potenti could add upsid
increas estim primarili due lower tax rate increas revenu
annual due strong humira momentum weaker
usd also lower estim tax rate
rais ep
ep estim revis new vs old vs
new pt base new ep increas pt
old ep new ep price-to-earnings
multipl in-lin peer median reflect strong ep cash flow
growth near term off-set concentr drug humira estimate
earn set face biosimilar competit januari possibl
flow prospect robust could pursu addit
estim gener free cash flow ocf less capital-expenditure
next year repres current ev market cap
net debt respect net dividend project
next five year less estimate div
risk-adjust pipelin estim repres total
sale beyond line extens opportun key drug
imbruvica venclexta pipelin compel could
upsid project asset valid project top
pipelin candid estim risk-adjust sale follow
upadacitinib ra crohn atop dermat ulcer
coliti
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
risankizumab psoriasi psoriat arthriti crohn ulcer
coliti
rova-t /stemcentryx platform cancer
biosimilar humira sandoz ipr patent challeng develop
mulitpl ipr february-april
risankizumab autoimmun diseas file approv
upadacitinib autoimmun diseas phase data ra
vs humira select-compar vs select-earli also fda
decis baricitinib drive percept
rova-t small cell lung cancer triniti pivot data file
elagolix fda action endometriosi without hormon add-back prioriti
review grant oct
pt base base case ep in-
line current peer median reflect strong ep growth
counterbalanc risk long-term humira declin earli next
bull case ep
bull case ep
financi upsid plu add new revenu driver diversifi
beyond humira humira imbruvica sale exceed estim
drive ep project pipelin develop deliv upsid surpris
 add new long-term growth driver help price-to-earnings
base case ep
base case ep
see balanc risk-reward robust ep growth off-set
long-term humira eros risk expect strong ep growth posit
pipelin develop near term balanc humira biosimilar threat
includ risk us biosimilar interchang
bear case ep
bear case ep
piplein candid falter fear humira biosimilar grow
due blood clot risk disappoint stemcentryx rova-t small cell lung
cancer data ep forecast biosimilar humira threat includ
neg patent news interchang progress caus concern
disappoint investor
equal-weight share
robust ep growth
growth near-medium term
balanc risk price-to-earnings contract long term
us biosimilar humira entri approach
near-medium term roll us
like pursu extern
transact enhanc pipelin
biosimilar anti-tnf remicad
humira imbruvica sale trends/outlook
financi result rel expect
extern busi develop
risk achiev price
upsid risk result
posit humira patent news value-
downsid risk result
disappoint problemat legal
price
price
price
compani data thomson reuter morgan stanley research valuat methodolog risk associ price target referenc
research report pleas contact client support follow us/canada hong kong latin america
 london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
exhibit trade mean year histor mean
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
